Hemanth Ramaprakash1, Cory M Hogaboam. 1. Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109-2200, USA.
Abstract
BACKGROUND: CpG administration abolishes airway inflammation and remodeling in acute models of allergic airway disease. METHODS: Herein, we investigated the therapeutic effect of CpG in a chronic fungal model of asthma. TLR9+/+ and TLR9-/- mice were sensitized to soluble Aspergillus fumigatus antigens and challenged with live A. fumigatus conidia. Mice were treated with intraperitoneal (IP) or intranasal (IN) CpG, or left untreated 14-28 days after conidium challenge. All features of allergic airway disease were attenuated in TLR9+/+ mice treated with IN CpG, including airway hyperresponsiveness (AHR), mucus production, and peribronchial fibrosis. RESULTS: TLR9-/- mice treated with IN CpG exhibited attenuated airway remodeling but not AHR. Whole-lung IL-12 levels were significantly elevated in both TLR9+/+ and TLR9-/- mice receiving IN CpG but not in either group receiving IP CpG. Whole-lung IL-10 levels were significantly elevated in IN CpG-treated TLR9+/+ mice but not in TLR9-/- mice receiving IN CpG. Increased whole-lung transcript and protein levels of the scavenger receptors SR-A and MARCO were observed in TLR9-/- mice compared with TLR9+/+ mice, possibly accounting for the CpG responsiveness in the knockout group. CONCLUSIONS: Together, these data show that IN CpG has a therapeutic effect during established fungal asthma, which is TLR9 dependent and independent. Copyright 2009 S. Karger AG, Basel.
BACKGROUND: CpG administration abolishes airway inflammation and remodeling in acute models of allergic airway disease. METHODS: Herein, we investigated the therapeutic effect of CpG in a chronic fungal model of asthma. TLR9+/+ and TLR9-/- mice were sensitized to soluble Aspergillus fumigatus antigens and challenged with live A. fumigatus conidia. Mice were treated with intraperitoneal (IP) or intranasal (IN) CpG, or left untreated 14-28 days after conidium challenge. All features of allergic airway disease were attenuated in TLR9+/+ mice treated with IN CpG, including airway hyperresponsiveness (AHR), mucus production, and peribronchial fibrosis. RESULTS:TLR9-/- mice treated with IN CpG exhibited attenuated airway remodeling but not AHR. Whole-lung IL-12 levels were significantly elevated in both TLR9+/+ and TLR9-/- mice receiving IN CpG but not in either group receiving IP CpG. Whole-lung IL-10 levels were significantly elevated in IN CpG-treated TLR9+/+ mice but not in TLR9-/- mice receiving IN CpG. Increased whole-lung transcript and protein levels of the scavenger receptors SR-A and MARCO were observed in TLR9-/- mice compared with TLR9+/+ mice, possibly accounting for the CpG responsiveness in the knockout group. CONCLUSIONS: Together, these data show that IN CpG has a therapeutic effect during established fungal asthma, which is TLR9 dependent and independent. Copyright 2009 S. Karger AG, Basel.
Authors: V P Kurup; J Q Xia; R Crameri; D A Rickaby; H Y Choi; S Flückiger; K Blaser; C A Dawson; K J Kelly Journal: Clin Immunol Date: 2001-03 Impact factor: 3.969
Authors: D H Broide; G Stachnick; D Castaneda; J Nayar; M Miller; J Y Cho; M Roman; J Zubeldia; T Hayashi; E Raz; T Hyashi Journal: J Clin Immunol Date: 2001-05 Impact factor: 8.317
Authors: Silvia Bozza; Roberta Gaziano; Grayson B Lipford; Claudia Montagnoli; Angela Bacci; Paolo Di Francesco; Viswanath P Kurup; Hermann Wagner; Luigina Romani Journal: Microbes Infect Date: 2002-11 Impact factor: 2.700
Authors: Jane M Schuh; Christine A Power; Amanda E Proudfoot; Steven L Kunkel; Nicholas W Lukacs; Cory M Hogaboam Journal: FASEB J Date: 2002-06-21 Impact factor: 5.191
Authors: Hemanth Ramaprakash; Takehiko Shibata; Karen E Duffy; Ugur B Ismailoglu; Rachel M Bredernitz; Ana Paula Moreira; Ana L Coelho; Anuk M Das; Natalie Fursov; Geoffrey L Chupp; Cory M Hogaboam Journal: Am J Pathol Date: 2011-05-14 Impact factor: 4.307
Authors: Matthew G Drake; Scott E Evans; Burton F Dickey; Allison D Fryer; David B Jacoby Journal: Am J Respir Cell Mol Biol Date: 2013-06 Impact factor: 6.914
Authors: Jeanette Wagener; R K Subbarao Malireddi; Megan D Lenardon; Martin Köberle; Simon Vautier; Donna M MacCallum; Tilo Biedermann; Martin Schaller; Mihai G Netea; Thirumala-Devi Kanneganti; Gordon D Brown; Alistair J P Brown; Neil A R Gow Journal: PLoS Pathog Date: 2014-04-10 Impact factor: 6.823